Kriya Therapeutics Secures $313.3 Million in New Funding to Advance Gene Therapy Pipeline
Kriya
Gene Therapy New Drug Developer
A rare opportunity, don't miss it!
The Opportunity for Financing is Here!~ Multiple well-known VC firms are seeking high-quality investment targets, Pipelines of interest include: (1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Self-immune innovative drugs with new targets/new MOA. Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
A rare opportunity, don't miss it!
The Opportunity for Financing is Here!~ Multiple well-known VC firms are seeking high-quality investment targets, Pipelines of interest include: (1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Self-immune innovative drugs with new targets/new MOA. Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
A rare opportunity, don't miss it!According to the latest information,Gene TherapyCompanyKriya Therapeutics ("Kriya" for short)Raised $313.3 million in a new round of financing.
Kriya was founded in 2019, and itsThe founders have held senior positions in gene therapy companies such as Spark Therapeutics, AveXis, and Sangamo Therapeutics.，ItsPioneeringKriyaThePurposeMainYesIn order toDevelopmentA series ofGene TherapyTo solveChronic Disease。
ThroughAcquisition，KriyaThePipelineInShort-termInThanks toFastEnrich。Currently，KriyaTotal9ArticlePipelineIn Development，RespectivelyFocusOphthalmologyDisease、MetabolismDiseaseAndNerveRelevantDisease。Among whichThere isTwo versionsAlreadyEnterClinicalPhase，RespectivelyKRIYA-825（Map-likeAtrophy）AndKRIYA-748（ThreeForkNeuralgia）。The RestSeveralStillAll are inClinicalBeforeStage。In addition, Kriya's proprietary computational engine SIRVE can integrate large amounts of data generated by the company’s engineered and high-throughput screening platforms, supporting machine learning-powered analysis and intelligent product design.
Image Source:Kriya Official Website
SelfEstablishmentTo date，Kriya was respectively in May 2020, July 2021, May 2022, and July 2023.ObtainMultiple rounds of financing，AddThis timeFinancingAmount，CumulativeFinancingAmountAlreadyExceed9Hundred MillionDollar。LatestTheSECFileCNNot disclosedKriyaThis roundFinancingTheInvestor IdentityAndUse of Funds，OnlyRevealThere isTwo investment institutions participated in this round of financing.
According toForeign MediaDisclosure，KriyaTheThis round of financingAmountCanIncludedBiologyPharmaceuticalsYearFinancingAmountHighestTheArrayChina。2025YearAs ofCurrently，BiologyPharmaceuticalsFieldFinancing AmountHigher thanKriyaThisFinancingTheOnlyFour Companies，Respectively：
1. Isomorphic Labs：The companyFocusAIPharmaceuticalsField，YesFromGoogle DeepMind DepartmentPeelingCome outThe。2025Year3MonthTime，ThisCompanyObtain6Hundred MillionDollarFinancing，Rong DengFirst Half of the YearBiologicalPharmaceuticalsFinancingListTop。
2. Verdiva Bio：The companyFocusCurrentlyThese two yearsThePopularDiseaseTrack——ObesitySymptom。2025Year4Month，ThisCompanyObtain4.11Hundred MillionDollarARound of Financing，AndSubsequentlyBy virtue ofThisPenFundsFromIn ChinaIntroductionMultipleGLP-1Pipeline（IncludingOralAndInjection）
3. Pathos AI：The companySimilarlyFocusAIPharmaceuticalsField，CoreProductYesAFromNovo NordiskIntroductionTheClinical StageTheProstate CancerProduct。2025Year5Month，ThisCompanyObtain3.65Hundred MillionDollarDRound Financing。
4. Eikon Therapeutics：TheCompanyFocusCancer、InflammationAndNerveSystemetc.VariousDiseaseField，CoreProductYesEIK1001——A Toll-like receptor agonist for the treatment of advanced melanoma.2025Year2Month，ThisCompanyObtain3.51Hundred MillionDollarTheDWheelFinancing。
Summary
KriyaThis round3.133Hundred MillionDollar'sFinancing，On the one handThanks toItsFocusTheYesCanFromGeneLevelUpChangeDisease，AndHopefulAchieveOnce and for allTheGene Therapy，AnotherAspectThenYesBecauseItsFocusTheThreeDiseaseFieldAll areAt presentMoreAffectedCapitalAndMarketFavorTheDirection。
Currently，PharmTimesStudyYuanShouldIndustryDemand，DecisionIn2025Year9Month26-27DayInShanghaiHost“CellTreatmentProductCMCR&DAndProductionQualityManagement”Activity（Offline）。ActivityFortunatelyInvitationArrivedMostlyIndustrySenior Expert，Will be translated asRegulatory Environment for Cell Therapy, CMC Development and Change of Cell Therapy Products, Comprehensive Management of Production Quality and Regulationsetc.MultipleAspectProceedTrainingIntroduction。This FieldActivityAimed at helping professionals in the cell therapy field enhance their systematic theoretical and practical skills. The target audience includes professionals and managers engaged in CMC research and development, production quality management, and registration in the cell therapy field, as well as practitioners interested in this area.WelcomeInterestedTheReaderRegistrationParticipate。
Scan to Register
2.https://www.biospace.com/business/the-top-five-biopharma-venture-capital-raises-of-h1-2025
3.https://www.biospace.com/business/gene-therapy-specialist-kriya-raises-313m
4. Other Public Information
2025-08-19
2025-08-19
2025-08-19
Copyright Statement/Disclaimer
This article is an original article.
This article is for informational exchange purposes only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website or the internet, or used in accordance with the CC0 protocol. All copyrights belong to the respective owners, and PharmaTimes makes every effort to credit the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
